循环sDPP-4在肥胖和胰岛素抵抗中升高但与系统性代谢炎症无关
该研究在451名不同代谢表型人群中检测血清sDPP-4,并在101人接受三种减重干预时动态观察。结果显示sDPP-4随年龄和体重增加,与胰岛素抵抗和高甘油三酯血症正相关,但在显性2型糖尿病中降低;与系统性炎症标志物无关联,而与肝功能和肾功能指标相关,减重干预中sDPP-4变化与肝功能改善相关而非体重变化。
要点
- sDPP-4随年龄和体重增加,与胰岛素抵抗和髙甘油三酯血症正相关。
- sDPP-4与系统性炎症标志物无关,不支持其作为脂肪因子参与代谢炎症。
- 减重干预中sDPP-4变化与肝功能改善相关,而非体重变化。
核心结论
- sDPP-4与肥胖中的肝脏异常相关,而非主要作为脂肪因子发挥作用。
- sDPP-4参与葡萄糖和脂质代谢,但不 fundamentally 参与系统性炎症。
研究设计与样本
- 研究纳入451名不同代谢表型的人类队列,以及101名接受三种减重干预的受试者。
- 通过酶联免疫吸附测定检测血清sDPP-4浓度,并与表型数据(包括肠道微生物组分析)关联。
主要发现
- sDPP-4随年龄和体重增加,与胰岛素抵抗和高甘油三酯血症正相关。
- 在显性2型糖尿病中sDPP-4降低,在动脉高血压受试者中血清sDPP-4浓度降低。
- 未发现sDPP-4与系统性炎症标志物相关。
- 肾功能和肝功能受损显著改变sDPP-4浓度,但与心力衰竭生物标志物无关。
- 在手术(胃旁路术和袖状胃切除术)和非手术减重干预中,sDPP-4与肝功能试验改善显著相关,但与体重变化无关。
临床怎么用
- sDPP-4可能反映肥胖相关的肝脏异常,而非系统性炎症状态。
- 在解读sDPP-4水平时需考虑年龄、体重、肾功能、肝功能、高血压和2型糖尿病状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Dipeptidylpeptidase (DPP)-4 is a key regulator of the incretin system. It exists in a membrane-bound form and a soluble form (sDPP-4). Initial human studies suggested sDPP-4 to be an adipokine involved in metabolic inflammation. However, recent mechanistic data in genetically modified mice has questioned these findings. OBJECTIVES: We examined circulating sDPP-4 in a cohort of n = 451 humans with different metabolic phenotypes and during 3 different weight loss interventions (n = 101) to further clarify its role in human physiology and metabolic diseases. DESIGN: sDPP-4 serum concentrations were measured by enzyme-linked immunosorbent assay and related to several phenotyping data including gut microbiome analysis. RESULTS: sDPP-4 increased with age and body weight and was positively associated with insulin resistance and hypertriglyceridemia but was reduced in manifest type 2 diabetes. In addition, we found reduced serum concentrations of sDPP-4 in subjects with arterial hypertension. In contrast to earlier reports, we did not identify an association with systemic markers of inflammation. Impaired kidney and liver functions significantly altered sDPP-4 concentrations while no relation to biomarkers for heart failure was observed. Having found increased levels of sDPP-4 in obesity, we studied surgical (gastric bypass and sleeve gastrectomy) and nonsurgical interventions, revealing a significant association of sDPP-4 with improvement of liver function tests but not with changes in body weight. CONCLUSIONS: Our data suggest that sDPP-4 is related to hepatic abnormalities in obesity rather than primarily functioning as an adipokine and that sDPP-4 is implicated both in glucose and in lipid metabolism, but not fundamentally in systemic inflammation.
引用
- Rohmann N, Schlicht K, Geisler C, et al. Circulating sDPP-4 is Increased in Obesity and Insulin Resistance but Is Not Related to Systemic Metabolic Inflammation. J Clin Endocrinol Metab. 2021. PMID: 33084870. doi:10.1210/clinem/dgaa758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。